Efficient Inhibition of Pathologic Angiogenesis using Combination Therapy of Anti-Epcam and Anti-VEGFR2 Nanobodies

Area of Science:

• Oncology
• Immunotherapy
• Biotechnology

Background:

• Epithelial cell adhesion molecule (EpCAM) and vascular endothelial growth factor receptor 2 (VEGFR2) are key targets in angiogenesis and tumorigenesis.
• Developing novel therapeutics to inhibit tumor cell proliferation and angiogenesis is crucial for cancer treatment.
• Nanobodies offer unique properties making them promising candidates for cancer therapy.

Purpose of the Study:

• To evaluate the synergistic inhibitory effects of combined anti-EpCAM and anti-VEGFR2 nanobodies on cancer cell lines.
• To assess the efficacy of this combination therapy in both in vitro and in vivo cancer models.

Main Methods:

• In vitro assays including MTT, cell migration, and tube formation were performed on MDA-MB231, MCF7, and HUVEC cells.
• In vivo studies utilized Nude mice bearing MDA-MB-231 tumors to evaluate therapeutic efficacy.
• The inhibitory activity of individual and combined nanobodies was assessed.

Main Results:

• The combination of anti-EpCAM and anti-VEGFR2 nanobodies significantly inhibited proliferation, migration, and tube formation in MDA-MB-231 cells compared to monotherapy (p < 0.05).
• Combined nanobody treatment markedly reduced tumor growth and volume in a preclinical mouse model (p < 0.05).

Conclusions:

• The combined administration of anti-EpCAM and anti-VEGFR2 nanobodies demonstrates potent anti-cancer activity.
• Combination therapy represents a promising and efficient strategy for future cancer treatment development.